单一肿瘤中心恶性胸腔积液患者的特征

Sharif Othman¹, Mohammad A¹, Khayyer ¹, Firas Hussein²
1、叙利亚蒂什林大学医院肺科
2、叙利亚蒂什林大学医院血液科

摘要

恶性胸腔积液被定义为含有肿瘤细胞的积液。尽管取得了进展，但它的治疗是姑息性的，平均存活率很 低。预后因许多因素而异。由于这种差异，很难预测预后。因此，根据患者的存活率及其与这些因素的相关性，我们 能够得出结果，为与诊断和治疗方法相关的未来研究服务。这是一项针对 2020 年 1 月至 2020 年 6 月期间来自单一肿 瘤中心的恶性和半恶性胸腔积液患者的观察性、前瞻性研究。记录了患者的完整特征。生存时间从诊断胸腔积液到死 亡或一年后计算，以先发生者为准。最终患者人数为 89 人。我们依靠 IBM SPSS Statistics Version 20 程序来计算统计 参数并分析结果。男性患者在我们的研究中占主导地位，60 岁以下的患者也是如此。肺肿瘤是最常见的原因。组织学 上，腺癌占最大比例。腺癌对生存率的影响具有统计学意义(P<0.001)并且具有临床意义，大大降低了这些比率。最 后，胸膜固定术是提高生存率的一个统计学显着因素(P=0.04)。恶性胸腔积液与低生存率相关。肺肿瘤是最常见的 原因，而腺癌是最常见的组织学类型，它在降低生存率方面具有重要的统计学意义。最后，胸膜固定术与显着更好的 生存时间相关。

关键词

恶性胸腔积液；肺癌；腺癌；胸膜固定术

参考

[1] Anderson, C. B., Philpott, G. W., & Ferguson, T. B. (1974). The treatment of malignant pleural effusions. Cancer, 33(4), 916–922. AID-CNCR2820330405 >3.0.CO;2-U

[2] Anevlavis, S., Kouliatsis, G., Sotiriou, I., Koukourakis, M. I., Archontogeorgis, K., Karpathiou, G., Giatromanolaki, A., & Froudarakis, M. E. (2014). Prognostic Factors in Patients Presenting with Pleural Effusion Revealing Malignancy. Respiration, 87(4), 311–316.

[3] Antony, V., Loddenkemper, R., Astoul, P., Boutin, C., Goldstraw, P., Hott, J., Panadero, F. R., & Sahn, S. (2001). Management of malignant pleural effusions. European Respiratory Journal, 18(2), 402–419.

[4] Asakura, H., Togami, T., Mitani, M., Takashima, H., Yokoe, K., Yamamoto, Y., Nishiyama, Y., Monden, T., Toyama, Y., & Ohkawa, M. (2005). The usefulness of FDG-PET imaging for the radiotherapy treatment planning of pyothorax-associated lymphoma. Annals of Nuclear Medicine, 19(8), 725–728.

[5] Bikmalla, S., Khalil, M., Ganaie, M., & Haris, M. (2013). Characteristics of malignant pleural effusions. Review of one-year data from a large tertiary center. European Respiratory Journal, 42(Suppl 57).

[6] Heffner, J. E., Highland, K., & Brown, L. K. (2003). A Meta-analysis Derivation of Continuous Likelihood Ratios for Diagnosing Pleural Fluid Exudates. American Journal of Respiratory and Critical Care Medicine, 167(12), 1591–1599.

[7] Heffner, J. E., Nietert, P. J., & Barbieri, C. (2000). Pleural Fluid pH as a Predictor of Survival for Patients With Malignant Pleural Effusions. Chest, 117(1), 79–86.

[8] Henschke, C. I., Yankelevitz, D. F., & Davis, S. D. (1991). Pleural diseases: Multimodality imaging and clinical management. Current Problems in Diagnostic Radiology, 20(5), 157–181. (91)90021-s [9] Hirata, T., Yonemori, K., Hirakawa, A., Shimizu, C., Tamura, K., Ando, M., Katsumata, N., Tanimoto, M., & Fujiwara, Y. (2011). Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients. European Respiratory Journal, 38(6), 1425–1430.

[10] Jeba, J., Cherian, R., Thangakunam, B., George, R., & Visalakshi, J. (2018). Prognostic factors of malignant pleural effusion among palliative care outpatients: A retrospective study. Indian Journal of Palliative Care, 24(2), 184.

[11] Özyurtkan, M. O., Balcı, A. E., & Çakmak, M. (2010). Predictors of mortality within three months in the patients with malignant pleural effusion. European Journal of Internal Medicine, 21(1), 30–34.

[12] Prakash, U. B., & Reiman, H. M. (1985). Comparison of Needle Biopsy With Cytologic Analysis for the Evaluation of Pleural Effusion: Analysis of 414 Cases. Mayo Clinic Proceedings, 60(3), 158–164.

[13] Rice, T. W., Rodriguez, R. M., Barnette, R., & Light, R. W. (2006). Prevalence and characteristics of pleural effusions in superior vena cava syndrome. Respirology, 11(3), 299–305. 2006.00841.x [14] Sahn, S. A. (1988). The Pleura. American Review of Respiratory Disease, 138(1), 184–234.

[15] Stathopoulos, G. T., & Kalomenidis, I. (2012). Malignant Pleural Effusion. American Journal of Respiratory and Critical Care Medicine, 186(6), 487–492.

[16] Wei, Y., Yu, Q., & Luo, H. (2009). Zhongguo Fei ai Za Zhi. Chinese journal of lung cancer, 12(3), 222–226.